MediPharm Labs (TSE:LABS)
TSX:LABS
Want to see TSE:LABS full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced clear near-term challenges—most notably a ~16.7% YoY revenue decline, a widened net loss and industry reimbursement headwinds—with several material positives: return to positive adjusted EBITDA, a strong 37% gross margin, meaningful operating expense reductions (‑14% YoY, ‑28% sequential), $1.0M in expected annualized savings, $9.9M cash and limited debt, and continued international commercial traction (France, New Zealand, Brazil, Germany). Management emphasizes disciplined, margin-focused execution and long-term pharma optionality supported by rare regulatory credentials. Given the company's demonstrated ability to protect margins, improve profitability metrics and maintain liquidity while advancing international expansion, the tone is cautiously optimistic.Company Guidance
Revenue and Channel Mix
Q1 revenue of $9.0M (down from $10.8M in Q1 2025, a decline of ~16.7%) with international medical representing $4.6M or ~51% of total revenue, underscoring the strength and contribution of regulated international channels.
High Gross Margin
Gross profit was $3.3M, representing a 37% gross margin — described as among the higher gross margins the company has achieved, reflecting disciplined product mix and branded international sales.
Return to Positive Adjusted EBITDA
Adjusted EBITDA returned to positive $0.1M for the quarter, demonstrating improved margin quality and the ability to offset near-term revenue pressure with operating discipline.
Cost Reductions and Operating Leverage
Total operating expenses were $4.2M, down 14% year-over-year and 28% sequentially; a restructuring program executed in Q1 is expected to deliver approximately $1.0M of annualized cost savings beginning in Q2.
Strong Balance Sheet and Liquidity
Exited the quarter with $9.9M in cash, virtually no debt, and current on excise taxes, sales taxes and trade payables, providing flexibility to fund operations and pursue selective M&A or partnerships.
Commercial Execution and International Expansion
Key commercial milestones: first shipments to France (initially shipped in Q4 2025) with a second purchase order in Q1 and further Q2 shipments planned; expansion into New Zealand with Beacon shipments; additional purchase order from Brazil with shipments expected in Q2; Germany delivered 14% sequential growth.
Pharma & Research Optionality
Regulatory and manufacturing credentials (FDA-inspected facility, Health Canada drug establishment license, EU GMP, etc.) position MediPharm for pharmaceutical and clinical research opportunities—U.S. rescheduling to Schedule III is cited as a long-term positive and the company reports increased inbound interest from research institutions for API supply.
TSE:LABS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:LABS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | C$0.08 | C$0.09 | +12.50% |
Mar 30, 2026 | C$0.07 | C$0.07 | 0.00% |
Nov 13, 2025 | C$0.07 | C$0.07 | 0.00% |
Aug 14, 2025 | C$0.09 | C$0.08 | -11.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MediPharm Labs (TSE:LABS) report earnings?
MediPharm Labs (TSE:LABS) is schdueled to report earning on Aug 17, 2026, TBA (Confirmed).
What is MediPharm Labs (TSE:LABS) earnings time?
MediPharm Labs (TSE:LABS) earnings time is at Aug 17, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:LABS EPS forecast?
TSE:LABS EPS forecast for the fiscal quarter 2026 (Q2) is >-0.01.